newsfilter
← Latest News
GlobeNewswire·

Alector Reports Third Quarter 2025 Financial Results and Provides Business Update

Selected lead candidates AL137 for the company's Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its ABC-enabled GCase enzyme replacement therapy in Parkinson's